

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LUCI DAVID P</u> (Last) (First) (Middle) <u>8285 EL RIO STREET,</u> <u>SUITE 130</u> (Street) <u>HOUSTON TX 77054</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>PLx Pharma Inc. [PLXP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/17/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Options	\$1.8 ⁽¹⁾	01/17/2017		A		275,000 ⁽¹⁾		(2)	01/17/2022	Common Stock	275,000 ⁽¹⁾	\$0	275,000 ⁽¹⁾	D		
Options	\$13.93 ⁽¹⁾	04/19/2017		D			298,826 ⁽¹⁾		03/18/2014	03/18/2019	Common Stock	298,826 ⁽¹⁾	\$0 ⁽³⁾	0	D	

Explanation of Responses:

- Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017.
- Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.).
- Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger.

/s/ David P. Luci 04/20/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.